Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS views and news. Opt-in with us: www.register.msviewsandnews.org


~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.


Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================================================


Wednesday, April 25, 2018

#AAN2018 – Celgene to Present Latest Data on Ozanimod’s Safety and Effectiveness

Celgene’s oral treatment candidate ozanimod can effectively reduce relapse rates in multiple sclerosis (MS) patients with mild to moderate disability, results of two Phase 3 trials show.
The company will present data on the SUNBEAM (NCT02294058) and RADIANCE (NCT02047734) trials in two presentations at the 2018 Annual Meeting of the American Academy of Neurology (AAN), underway in Los Angeles through April 27.
Both studies evaluated the efficacy and safety of 1 mg or 0.5 mg capsules of ozanimod compared to intramuscular injections of 30 μg of Biogen’s Avonex(interferon beta-1a) in a total of 2,659 people with relapsing MS.
During the SUNBEAM trial, patients treated daily with both ozanimod doses experienced fewer relapses per year compared to those treated with Avonex — 0.195 with ozanimod at 1 mg, 0.210 with Ozanimod at 0.5 mg, and 0.338 for those given Avonex as a weekly injection, the data show.
This beneficial effect was found both in patients new disease-modifying therapies, as well as in those who had already used such therapies.
Similar results were also reported in the RADIANCE trial, which evaluated the treatment’s effectiveness over 24 months. Both ozanimod doses were seen to be more effective in reducing annualized relapse rates (ARR) than Avonex — 0.157 and 0.228 with ozanimod 1 and 0.5 mg, respectively, and 0.246 with Avonex.
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

No comments: